PROSPECTIVE INTERVENTIONAL STUDY OF ASSESS FUNCTIONAL OUTCOME OF GIANT CELL TUMOUR OF DISTAL END RADIUS TREATED BY EN BLOE RESECTION AND RECONSTRUCTION BY ULNAR TRANSLOCATION

Background: Giant cell tumour (GCT) of bone is a relatively rare, locally aggressive benign neoplasm associated with a wide pathological spectrum, ranging from latent benign to highly recurrent and, occasionally, malignant metastatic potential. Methods: This retrospective study was conducted on 30 hospitalized patients for surgery in in Jaipur. We followed up all patients with GCT of the distal radius who were treated with en bloc excision and custom prosthetic replacement. All cases were evaluated based on clinical and radiological examinations, passive range of motion (ROM) of the wrist joint, complications, and Musculoskeletal Tumor Society (MSTS) score. Results: Mean follow-up period was 52.36 months, mean resected length of the radius was 7.11±2.31 cm. One patient had tumor recurrence in the soft tissues after 16.32±2.31 months (recurrence rate 10.00 %). No patient had fracture, recurrence in the bone, metastases, or immune rejection. No complications were seen, such as loosening, rupture, or dislocation of the custom prosthesis. One patient developed superficial infection at the operative site which resolved after a course of antibiotics for 4 weeks. One patient experienced pain, which could be endured without the need for analgesics. Average ROM was 40.6° of dorsiflexion, 29.8° of volar flexion, 46.2° of supination, and 37.8° of pronation. Mean grip strength was 70 % (41–84 %). Overall revised MSTS score averaged 81.36 % with one being excellent, five good, and five satisfactory. Conclusion: The optimal treatment for GCTs arising around the knee remains controversial. Despite the trend towards better oncological control of this tumour after wide resections, the recurrence rates achieved through a more conservative procedure such as the curettage-based interventions seem to be acceptable. Additionally, curettage and local adjuvants allow for overall better function of the knee, in particular with proximal tibia GCTs. Keywords: GCT, MSTS, ROM

Download Full-text

Giant cell tumour of bone around the knee: a systematic review of the functional and oncological outcomes

EFORT Open Reviews ◽

10.1302/2058-5241.6.200154 ◽

2021 ◽

Vol 6 (8) ◽

pp. 641-650

Author(s):

Joaquim Soares do Brito ◽

André Spranger ◽

Paulo Almeida ◽

José Portela ◽

Irene Barrientos-Ruiz

Keyword(s):

Systematic Review ◽

Giant Cell ◽

Proximal Tibia ◽

Giant Cell Tumour ◽

Benign Neoplasm ◽

Cell Tumour ◽

Long Bone ◽

Musculoskeletal Tumor ◽

Musculoskeletal Tumor Society ◽

Oncological Outcomes

Giant cell tumour of bone (GCT) is a relatively rare, locally aggressive benign neoplasm observed in the long bone epiphyseal-metaphyseal regions of young adults. The optimal treatment strategy for these tumours remains controversial, and a huge amount of contradictory data regarding the functional and oncological outcomes can be found. Therefore, we performed a systematic review intended to investigate the functional and oncological outcomes after surgical treatment of GCTs arising around the knee, namely in the distal femur and proximal tibia. A trend towards better oncological control was found using wide resections, nonetheless, curettage-based techniques achieve a highly acceptable recurrence rate with overall better knee function. A slight advantage favouring proximal tibia GCTs regarding the Musculoskeletal Tumor Society (MSTS) score was also observed. Prospective studies comparing groups of more homogeneous patients, tumours, and treatment options should be developed to obtain more conclusive and definitive results regarding the optimal strategy for treating GCTs. Cite this article: EFORT Open Rev 2021;6:641-650. DOI: 10.1302/2058-5241.6.200154

Download Full-text

Functional results of wrist arthrodesis versus arthroplasty with proximal fibula following giant cell tumour excision of the distal radius

Journal of Hand Surgery (European Volume) ◽

10.1177/1753193418809785 ◽

2018 ◽

Vol 44 (4) ◽

pp. 394-401 ◽

Cited By ~ 3

Author(s):

Huayi Qu ◽

Wei Guo ◽

Dasen Li ◽

Yi Yang ◽

Ran Wei ◽

...

Keyword(s):

Grip Strength ◽

Giant Cell ◽

Distal Radius ◽

Giant Cell Tumour ◽

Functional Results ◽

Cell Tumour ◽

Musculoskeletal Tumor Society ◽

Wrist Arthrodesis ◽

Proximal Fibula ◽

Radiocarpal Joint

Twenty-one patients underwent excision of a Campanacci grade III giant cell tumour of the distal radius and had reconstruction using a proximal fibula autograft. We compared the functional results of wrist arthrodesis versus arthroplasty. All 21 patients healed in an average of 8 months, and all have remained disease free. The Musculoskeletal Tumor Society 93, the Disabilities of the Arm, Shoulder, and Hand scores and the grip strength of the operated wrist compared with the contralateral wrist were 93%, 7, and 71% for the arthrodesis group and 83%, 17, and 40% for the arthroplasty group. Arthrodesis of the reconstructed radiocarpal joint provided better grip strength and functional outcomes than arthroplasty. Level of evidence: III

Download Full-text

RECURRENT GIANT CELL TUMOUR OF THE FLEXOR TENDON SHEATH OF THE DISTAL PALM – A CASE REPORT

10.36106/ijsr/4104883 ◽

2020 ◽

pp. 1-2

Author(s):

Surya Rao Rao Venkata Mahipathy ◽

Alagar Raja Durairaj ◽

Narayanamurthy Sundaramurthy ◽

Anand Prasath Jayachandiran ◽

Volga Harikrishnan

Keyword(s):

Giant Cell ◽

Giant Cell Tumour ◽

Flexor Tendon ◽

Imaging Modality ◽

Benign Lesion ◽

Tendon Sheath ◽

Cell Tumour ◽

Recurrence Rates ◽

Flexor Tendon Sheath ◽

Tenosynovial Giant Cell Tumour

Giant cell tumor of the tendon sheath is a common benign lesion of the hand. They are also known as tenosynovial giant cell tumours. Magnetic resonance imaging is the imaging modality of choice and the current treatment is surgical excision of the lesion. This lesion is particularly known for its high recurrence rates. Here, we present a case of a recurrent tenosynovial giant cell tumour of the flexor tendon sheath of the index finger at the distal palmar crease. Diagnosis was confirmed by MRI and the lesion was excised. Histopathology revealed a localized type of tenosynovial giant cell tumour.

Download Full-text

Inconclusive benefit of adjuvant 90Yttrium hydroxyapatite to radiosynovectomy for diffuse-type tenosynovial giant-cell tumour of the knee

The Bone & Joint Journal ◽

10.1302/0301-620x.100b7.bjj-2017-0867.r3 ◽

2018 ◽

Vol 100-B (7) ◽

pp. 984-988 ◽

Cited By ~ 4

Author(s):

Y. Gortzak ◽

M. Vitenberg ◽

T. Frenkel Rutenberg ◽

Y. Kollender ◽

S. Dadia ◽

...

Keyword(s):

Giant Cell ◽

Adjuvant Treatment ◽

Giant Cell Tumour ◽

Cell Tumour ◽

Diffuse Type ◽

Musculoskeletal Tumor Society ◽

Group A ◽

Tenosynovial Giant Cell Tumour ◽

Group B

Aims Intra-articular 90Yttrium (90Y) is an adjunct to surgical treatment by synovectomy for patients with diffuse-type tenosynovial giant-cell tumour (dtTGCT) of the knee, with variable success rates. Clinical information is, however, sparse and its value remains unclear. We investigated the long-term outcome of patients who underwent synovectomy with and without adjuvant treatment with 90Yttrium. Patients and Methods All patients with dtTGCT of the knee who underwent synovectomy between 1991 and 2014 were included in the study. Group A patients underwent synovectomy and an intra-articular injection of 90Yttrium between six and eight weeks after surgery. Group B patients underwent surgery alone. Results There were 34 patients in group A and 22 in group B. Recurrence of dtTGCT was identified by MRI, which was undertaken in patients with further symptoms. At a mean follow-up of 7.3 years (2.5 to 25.4), there was residual disease in 15 patients in group A and 11 in group B (p < 0.363). The mean Musculoskeletal Tumor Society (MSTS) score at final follow-up was 85% and 83%, respectively (p < 0.91). Conclusion There were no significant differences in outcome between patients treated surgically for dtTGCT of the knee with or without an adjuvant intra-articular injection of 90Yttrium. We were unable to provide conclusive evidence of any benefits derived from the adjuvant treatment. Cite this article: Bone Joint J 2018;100-B:984–8.

Download Full-text

An unusual case of giant cell tumour involving the middle cranial fossa, originating from soft tissues of the temporomandibular joint

Acta Neurochirurgica ◽

10.1007/s00701-009-0296-3 ◽

2009 ◽

Vol 151 (12) ◽

pp. 1685-1687 ◽

Cited By ~ 3

Author(s):

Luigi Chiarini ◽

Sabina Figurelli ◽

Angelo Ghidini ◽

Pier Francesco Nocini ◽

Pasquale Procacci ◽

...

Keyword(s):

Temporomandibular Joint ◽

Giant Cell ◽

Unusual Case ◽

Soft Tissues ◽

Giant Cell Tumour ◽

Middle Cranial Fossa ◽

Cell Tumour ◽

Cranial Fossa

Download Full-text

Comprehensive molecular imaging of malignant transformation of giant cell tumour of bone reveals diverse disease biology

BMJ Case Reports ◽

10.1136/bcr-2016-218839 ◽

2019 ◽

Vol 12 (4) ◽

pp. e218839 ◽

Cited By ~ 2

Author(s):

Kalevi Kairemo ◽

Wei-Lien Wang ◽

Vivek Subbiah

Keyword(s):

Molecular Imaging ◽

Bone Formation ◽

Lymph Nodes ◽

Giant Cell ◽

Malignant Transformation ◽

Soft Tissues ◽

Giant Cell Tumour ◽

Cell Tumour ◽

X Rays ◽

First Case

Malignant transformation of giant cell tumour of the bone is extremely rare. In addition, bone transformation in giant cell tumour may occur in different phases. With conventional X-rays, CT scans or MRIs, it may be challenging to distinguish among different phases of bone transformation, normal bone, soft tissue disease and bone disease (benign vs malignant lesions) and changes in multiple organs such as lung, liver and lymph nodes unless every lesion is biopsied, which is not practical. Molecular imaging with different isotopes (Tc-99m phosphonate, 2-deoxy-2-(18F)fluoro-d-glucose and sodium fluoride-18) may help to better characterise the disease. We hypothesised that molecular imaging could offer qualitative and quantitative characterisation of all stages of bone formation, destruction, reactivity or neoplasia in a patient with giant cell tumour of the bone, and we present the first case of molecular imaging where bone formation was seen in multiple soft tissues, such as lungs, muscles, lymph nodes and liver.

Download Full-text

Giant cell tumour of the middle phalanx of the middle finger

BMJ Case Reports ◽

10.1136/bcr-2018-229076 ◽

2019 ◽

Vol 12 (3) ◽

pp. e229076 ◽

Cited By ~ 1

Author(s):

Nath Adulkasem ◽

Dumnoensun Pruksakorn

Keyword(s):

Giant Cell ◽

Bone Grafting ◽

Giant Cell Tumour ◽

Middle Finger ◽

Cell Tumour ◽

Middle Phalanx ◽

Recurrence Rates ◽

Left Middle

Giant cell tumour (GCT) of bones in the hand is very rare, only 2% of all hand tumours, but unacceptably high recurrence rates (up to 90%) have been reported by several authors. Diagnosis can be challenging due to its rarity and enchondroma-mimicking characteristics. We report on a case of GCT of the middle phalanx of the left middle finger in a 49-year-old woman who underwent middle phalanx resection and reconstruction with bone grafting. At the 1-year follow-up, no evidence of recurrence was detected and the patient was pain-free.

Download Full-text